Maven Securities LTD Sells 22,785 Shares of Pfizer Inc. $PFE

Maven Securities LTD lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 47.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,415 shares of the biopharmaceutical company’s stock after selling 22,785 shares during the period. Maven Securities LTD’s holdings in Pfizer were worth $647,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Brighton Jones LLC raised its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. United Bank increased its stake in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Avantax Advisory Services Inc. increased its stake in shares of Pfizer by 14.6% during the 2nd quarter. Avantax Advisory Services Inc. now owns 423,497 shares of the biopharmaceutical company’s stock worth $10,266,000 after purchasing an additional 54,086 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its stake in Pfizer by 8.8% in the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 2,112,648 shares of the biopharmaceutical company’s stock valued at $51,211,000 after purchasing an additional 171,223 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 3.2%

Pfizer stock opened at $27.47 on Wednesday. The company’s 50-day moving average price is $26.57 and its two-hundred day moving average price is $25.56. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a market cap of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the company posted $0.63 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive topline Phase 2 results for its next‑generation CDK4 inhibitor atirmociclib in HR+/HER2‑ metastatic breast cancer — the combo reduced risk of progression or death by ~40% versus control, positioning atirmociclib as a potential successor to Ibrance and a meaningful oncology revenue driver if confirmed in later trials. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Major media and wire outlets (Reuters/BusinessWire) highlighted the trial win and its magnitude (40% risk reduction), which is driving optimism around Pfizer’s oncology strategy and helps the stock’s re‑rating story. Reuters: Pfizer experimental breast cancer drug cuts risk
• Positive Sentiment: HSBC raised its price target to $32 and maintained a Buy rating, giving institutional support and signaling ~16% upside to analysts’ consensus targets — a catalyst for near‑term buying. Benzinga: HSBC raises Pfizer PT
• Positive Sentiment: Competitive dynamics improved after a rival (Bicycle) scaled back a Padcev challenger, reducing near‑term competitive pressure on Pfizer’s fast‑selling bladder cancer drug. That lowers some downside risk to future sales. BioPharmaDive: Bicycle layoffs, Padcev challenger deprioritized
• Neutral Sentiment: Jim Cramer and other commentators noted Pfizer’s sizable pipeline (retail interest), which can boost retail flows but doesn’t change fundamentals absent confirmatory Phase 3 data or regulatory actions. Yahoo: Jim Cramer on Pfizer pipeline
• Neutral Sentiment: Coverage and attention pieces (Zacks, IP Group mentions) point to rising investor focus and deal flow benefits (e.g., prior Metsera deal), but these are incremental until monetized or reflected in guidance. Zacks: Pfizer attracting attention
• Negative Sentiment: Longer‑term risk reminder: analysts and commentators caution that Pfizer still faces revenue pressure from loss of COVID exclusivity and other patent cliffs — positive trial news helps re‑rate but does not eliminate those macro risks. The Motley Fool: Key risks for Pfizer

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PFE shares. Royal Bank Of Canada started coverage on Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target for the company. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.14.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.